Energizing good fat by neurovascular development
- Institution
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX
- Principal investigator
- Alexes Daquinag
- Funding
- $176K
- Duration
- 2024–2025
Moonbase score
Still being scored
Abstract
ABSTRACT Vascular endothelial growth factor-A is a critical angiogenic factor that dramatically improves the vascularization in the obese adipose tissue, which thus protects transgenic mice not only against high-fat-diet-induced obesity but also insulin resistance. However, the precise mechanism underlining these metabolic benefits remains to be determined. Our preliminary results suggest that the function of vascular endothelial growth factor-A is associated with the upregulation of another angiogenic factor, angiopoietin-2. Moreover, Vascular endothelial growth factor-A stimulates sympathetic activation, enhancing lipolysis and energy expenditure in adipose tissue. This proposal is built upon these observations and the multitude of Vascular endothelial growth factor-A-related mouse models to dissect the complex physiological actions of this growth factor in adipose tissue. It is hypothesized that vascular endothelial growth factor-A synergistically interacts with angiopoietin-2 to form the functional new blood vessels in adipose tissue, promoting energy expenditure in a sympathetic activation- dependent manner. Specifically, two Aims are proposed: 1). To determine the role of angiopoietin-2 in vascular endothelial growth factor-A mediated angiogenesis in adipose tissue; 2). To investigate the mechanisms by which vascular endothelial growth factor-A-induced neuronal factors function on endothelial cells to improve angiogenesis in adipose tissue. The novel genetic models and pharmacological tools will be applied to achieve these Aims. Successful completion of the proposed studies will demonstrate the essential contribution of vascular endothelial growth factor-A to the dynamics of adipose tissue remodeling during both physiological (exercise and cold exposure) and pathological (obesity) conditions and highlight it as a factor with clinical significance in obesity and related diseases, which will provide insights for my independent R01 application.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of Texas Hlth Sci Ctr Houston60
Receptor-Targeted Fluorescence-Guided Surgery in Pancreatic Neuroendocrine Tumors
Ali Azhdarinia · $485K · 2022–2028
- NIH · University of Texas Hlth Sci Ctr Houston51
Optimizing mRNA sequences with deep neural networks
Xiaobo Zhou · $351K · 2024–2028
- NIH · University of Texas Hlth Sci Ctr Houston48
Development of a precision medicine platform for circadian based therapeutics in pancreatic cancer
Faraz Bishehsari · $1.5M · 2024–2027